We strive to contribute to groundbreaking therapies with ourscreenable, physiologically relevant 3D human disease models. By combining technological strengths and expertise, we establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases. For more information, visit: www.mimetas.com.

EASME - EU Executive Agency for SMEs

Zeeuws Investerings Fonds

Aglaia BioMedical Ventures

Cathay Venture

OostNL

InnovationQuarter

European Life Sciences Growth Fund

Korys

MIMETAS

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

SSL by Default

DNSSEC

LetsEncrypt

Cloudflare CDN

Cloudflare

jsDelivr

Facebook Sharer

Chief Technology Officer

Bas Trietsch

Director of Model Development

Henriette Lanz

Director of Manufacturing

Johnny Slot

Associate Director Biology Services

Nienke Wevers

Director of Business Development

Remko Vught

Associate Director TechCore

Todd Burton

Business Management

Yoko Ejiri

Scientific Project Lead

Bart Kramer

West Coast Territory Manager

Colin Dailey

Intellectual Property Manager

Jan-Paul Hoog

Mark Krul

Jos Joore

CEO and Co-Founder

Paul Vulto

Thomas Hankemeier

Co-Founder

Anthony Saleh

Director Product R&D

Jannick Cox

Board Observer

Eric van der Putten

Non Executive Director

Dwayne Dexter

Director, Mimetas US

Europe, Middle East, and Africa (EMEA) Health Care Companies (Top 10K)

Private Europe, Middle East, and Africa (EMEA) Companies (Top 10K)

European Union (EU) Companies (Top 10K)

Health Care Companies With More Than 10 Employees (Top 10K)

MIMETAS develops predictive Organ-on-a-Chip cell culture models for better, more reliable and tailored medicines. A significant gap exist between the predictive value of various in vitro and animal screening models and a patient. MIMETAS fills this gap with its OrganoPlates featuring organotypic screening models that have an improved predictability and can be screened at a high throughput.

Grant - Mimetas

Series B - Mimetas

Series A - Mimetas

Seed Round - Mimetas

Computer and Software Products and Electrical and Scientific Products

Leiden

Zuid-Holland

The Netherlands

Europe

Mimetas

Organ-On-Chip Market Size & Share Envisaged To Reach USD 1388.30 Million By 2032: Global Report by Polaris ...

Global Organ on Chip Market Report 2024-2033 Featuring ...

$1.6+ Bn Organ-on-Chip Market to Grow at 31.1% CAGR ...

$1.6+ Bn Organ-on-Chip Market to Grow at 31.1% CAGR, Globally, by 2030

8th Tumor Models San Francisco Summit 2024 | pharmaphorum

CN Bio taps into LifeNet Health to improve organ-on-a-chip ...

Dundee scientists create world-first 'micro placenta'

Organ-on-a-chip Market Size Worth USD 115.9 Million by ...

MIMETAS and Astellas Expand Partnership to Include Automation and Application Support

Czech Republic

Japan

Asia

United States

North America

United Kingdom

HTML5

Comodo PositiveSSL Certificates

jQuery

Vimeo

Sumo

Microsoft Outlook

DigiCert

Bootstrap

Amazon EC2

Google Cloud Translation API

Caladrius is a competitor of MIMETAS in the organ-on-a-chip products and tissue models for compound testing, screening, and fundamental research applications.

Caladrius

Ncardia competes with MIMETAS in the development of organ-on-a-chip products and tissue models for compound testing and screening.

Ncardia

Cesca is a direct competitor of MIMETAS in the organ-on-a-chip products and tissue models for compound testing and screening.

Cesca

Emulate is a competitor of MIMETAS in the development of an automated bio-emulation platform, offering various organ chips for testing and research purposes.

Emulate

TissUse operates as a biotechnology company and competes with MIMETAS in the development of tissue models and organ chips for research and testing applications.

TissUse

Stemnovate is a company focused on drug discovery and safety testing, offering innovative technologies for drug screening, including multi-organ modelling and automation for cell-based assays.

Stemnovate

MIMETAS is a leading company in the field of 3D disease modeling, providing unmatched disease relevance, precision, and throughput. The company is dedicated to leveraging its 3D tissue expertise to offer tailored solutions for unique research questions in drug discovery and compound analysis.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 16, 2024 9:48 PM	47450316
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 16, 2024 9:48 PM	e1635fcf
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	b4185360
crunchbase profile	general	Nov 19, 2024 11:27 AM	42d3dcbc
li profile	general	Feb 16, 2024 9:48 PM	6662a41c
translate crunchbase fundingrounds	general	Nov 19, 2024 1:27 PM	1329e2aa
peers	general	Feb 16, 2024 9:48 PM	879743a2
news basic	general	Feb 16, 2024 9:48 PM	b959cb85
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:MIMETAS

MIMETAS